SCHEMBL872486

SCHEMBL872486

CCCCCC/C=C\CCCCCCCCCC(CCCCCCCCC)N(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.48
TRPV1 Q8NER1 1/20 0.48
SPHK2 Q9NRA0 2/20 0.46
SPHK1 Q9NYA1 2/20 0.46
CETP P11597 1/20 0.46
CNR1 P21554 1/20 0.44
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
TERT O14746 3/20 0.42
CYP1A2 P05177 2/20 0.42
MAPT P10636 2/20 0.42
CYP2C19 P33261 2/20 0.42
BLM P54132 2/20 0.42
HSD17B10 Q99714 2/20 0.42
FABP4 P15090 2/20 0.42
PTPN1 P18031 2/20 0.42
PPARG P37231 2/20 0.42
KMT2A Q03164 2/20 0.42
PPARD Q03181 2/20 0.42
PPARA Q07869 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL872884 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL20197575 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL20197385 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL18398016 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL17047030 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL23437849 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL872193 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL20797268 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL21249045 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP
SCHEMBL19616579 1.00 FAAH (0.48) FAAHTRPV1SPHK2SPHK1CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 816 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240123047-A1 LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES MERCK SHARP & DOHME LLC (US) 2024-04-18 US claimed
US-11566051-B2 Stabilized RSV F proteins and uses thereof MERCK SHARP & DOHME LLC (US) 2023-01-31 US claimed
US-11413348-B2 Low molecular weight cationic lipids for oligonucleotide delivery SIRNA THEREPEUTICS, INC. (US) 2022-08-16 US claimed
EP-3943114-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY Sirna Therapeutics, Inc. (US) 2022-01-26 EP claimed
EP-3939604-A2 INFLUENZA HEMAGGLUTININ PROTEIN VACCINES Merck Sharp & Dohme Corp. (US) 2022-01-19 EP claimed
US-20210300971-A1 STABILIZED RSV F PROTEINS AND USES THEREOF MERCK SHARP & DOHME LLC 2021-09-30 US claimed
EP-3144015-B1 LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY SIRNA THERAPEUTICS INC (US) 2021-06-02 EP claimed
US-20200222540-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY SIRNA THERAPEUTICS, INC. (US) 2020-07-16 US claimed
EP-3556353-A2 LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS MERCK SHARP & DOHME CORP. (US) 2019-10-23 EP claimed
US-20190314486-A1 INFLUENZA HEMAGGLUTININ PROTEIN VACCINES MERCK SHARP & DOHME CORP. (US) 2019-10-17 US claimed
US-20190167811-A1 LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY MODERNATX, INC. 2019-06-06 US claimed
EP-3442590-A2 LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY Modernatx, Inc. (US) 2019-02-20 EP claimed
US-20180311176-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES TRANSLATE BIO MA, INC. (US) 2018-11-01 US claimed
WO-2017192470-A1 COMBINATION THERAPY OF ANTI-IL-10 ANTIBODY AND COMPOSITIONS COMPRISING LIPID NANOPARTICLES AND TLR9 AGONIST CPG OLIGONUCLEOTIDES MERCK SHARP & DOHME CORP. (US) 2017-11-09 WO claimed
WO-2017180917-A2 LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY MODERNATX, INC. (US) 2017-10-19 WO claimed
EP-3144015-A2 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY Sirna Therapeutics, Inc. (US) 2017-03-22 EP claimed
EP-3110401-A2 LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS Merck Sharp & Dohme Corp. (US) 2017-01-04 EP claimed
US-20160361411-A1 LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS MERCK SHARP & DOHME CORP (US) 2016-12-15 US claimed
WO-2015130584-A2 LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS MERCK SHARP & DOHME CORP. (US) 2015-09-03 WO claimed
US-20130178541-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY BANK OF AMERICA, N.A. 2013-07-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180311176-A1 NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACID COMPLEXES DIS3, SYNCRIP, EXOSC5 FAAH 3759/4885TRPV1 4841/4885SPHK2 3128/4885
US-20160361411-A1 LIPID NANOPARTICLE VACCINE ADJUVANTS AND ANTIGEN DELIVERY SYSTEMS TLR3, TLR5, TLR1 FAAH 955/4885TRPV1 188/4885SPHK2 1038/4885
US-20190167811-A1 LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY RNMT, PHOSPHO1, POLM FAAH 2350/4885TRPV1 3576/4885SPHK2 554/4885
US-20240123047-A1 LIPID NANOPARTICLE ADJUVANT COMPOSITION FOR PNEUMOCOCCAL CONJUGATE VACCINES PLTP, NAPEPLD, PHOSPHO1 FAAH 1516/4885TRPV1 4537/4885SPHK2 1378/4885
US-20130178541-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY LDLR, LIPC, CETP FAAH 3866/4885TRPV1 3041/4885SPHK2 185/4885
US-20200222540-A1 NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY LDLR, APOB, NPC1L1 FAAH 3408/4885TRPV1 3074/4885SPHK2 252/4885
US-11413348-B2 Low molecular weight cationic lipids for oligonucleotide delivery LDLR, APOB, CETP FAAH 3663/4885TRPV1 3436/4885SPHK2 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.